ATM kinase sustains HER2 tumorigenicity in breast cancer

Venturina Stagni (), Isabella Manni, Veronica Oropallo, Marcella Mottolese, Anna Di Benedetto, Giulia Piaggio, Rita Falcioni, Danilo Giaccari, Selene Di Carlo, Francesca Sperati, Maria Teresa Cencioni and Daniela Barilà ()
Additional contact information
Venturina Stagni: Laboratory of Cell Signaling, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia
Isabella Manni: Experimental Oncology, Regina Elena National Cancer Institute
Veronica Oropallo: Laboratory of Cell Signaling, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia
Marcella Mottolese: Regina Elena National Cancer Institute
Anna Di Benedetto: Regina Elena National Cancer Institute
Giulia Piaggio: Experimental Oncology, Regina Elena National Cancer Institute
Rita Falcioni: Experimental Oncology, Regina Elena National Cancer Institute
Danilo Giaccari: Laboratory of Cell Signaling, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia
Selene Di Carlo: Experimental Oncology, Regina Elena National Cancer Institute
Francesca Sperati: Biostatistic Unit, Scientific Direction, Regina Elena National Cancer Institute
Maria Teresa Cencioni: Laboratory of Neuroimmunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia
Daniela Barilà: Laboratory of Cell Signaling, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia

Nature Communications, 2015, vol. 6, issue 1, 1-10

Abstract: Abstract ATM kinase preserves genomic stability by acting as a tumour suppressor. However, its identification as a component of several signalling networks suggests a dualism for ATM in cancer. Here we report that ATM expression and activity promotes HER2-dependent tumorigenicity in vitro and in vivo. We reveal a correlation between ATM activation and the reduced time to recurrence in patients diagnosed with invasive HER2-positive breast cancer. Furthermore, we identify ATM as a novel modulator of HER2 protein stability that acts by promoting a complex of HER2 with the chaperone HSP90, therefore preventing HER2 ubiquitination and degradation. As a consequence, ATM sustains AKT activation downstream of HER2 and may modulate the response to therapeutic approaches, suggesting that the status of ATM activity may be informative for the treatment and prognosis of HER2-positive tumours. Our findings provide evidence for ATM’s tumorigenic potential revising the canonical role of ATM as a pure tumour suppressor.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms7886 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms7886

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms7886

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().